GlassScriptPhysician profile
Paul Darwin Mormon
NPI 1699768887
$9,726.43
in general payments reported to CMS, 2019-2025
13 companies · $112 in 2025
The $112 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,360 · 2020: $744 · 2021: $1,311 · 2022: $1,697 · 2023: $2,923 · 2024: $580 · 2025: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,032 · Food and Beverage: $1,582.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,032.22 |
| Food and Beverage | $1,582.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $3,103.13 | 2019-2025 | Total30, Precision7 |
| Carl Zeiss Meditec USA, INC. | $2,312.94 | 2023 | Clarus, Humphrey Field Analyzer (Hfa3), Forum |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $2,001.05 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $950.45 | 2022-2025 | Infuse, Miebo, Xiidra |
| Coopervision INC. | $629.89 | 2019-2024 | Myday Contact Lens, Misight Contact Lens |
| Allergan, INC. | $282.34 | 2020-2022 | |
| Johnson & Johnson Vision Care, INC. | $147.61 | 2019-2021 | |
| Maculogix, INC. | $94.00 | 2019 | |
| Optos, INC. | $87.16 | 2020-2021 | |
| Lkc Technologies, INC. | $51.07 | 2023-2024 | |
| Kala Pharmaceuticals, INC. | $34.94 | 2021 | |
| Novartis Pharmaceuticals Corporation | $16.92 | 2020 | |
| Heidelberg Engineering, INC. | $14.93 | 2024 | Spectralis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Mormon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.